April 10, 2014 / 11:25 AM / 3 years ago

Biogen's blood disorder drug succeeds in late-stage trial

April 10 (Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial.

The drug, Eloctate, was being developed as a treatment for haemophilia A - a rare genetic disorder in which a person’s blood does not clot properly due to missing or reduced levels of a particular protein. (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below